# KEYNOTE-013 (NCT01953692)

> A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab; pembrolizumab plus lenalidomide
- Indication: hematologic malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01953692
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Myelodysplastic Syndrome; Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Primary Mediastinal B-Cell Lymphoma
- Interventions: Pembrolizumab; Lenalidomide 20 mg; Lenalidomide 25 mg
- Enrollment: 197
- Primary outcome: Number of Participants Who Experienced One or More Adverse Events (AEs):
- Primary outcome: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
- Primary outcome: Objective Response Rate (ORR) in Cohort 1: Myelodysplastic Syndrome (MDS)
- Primary outcome: Objective Response Rate (ORR) in Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)
- Primary outcome: Complete Remission Rate (CRR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
- Primary outcome: Objective Response Rate (ORR) in Participants Pooled From the Cohort 4 Non-Hodgkin Lymphoma (NHL) Sub-Cohorts (Cohorts 4A+4B+4C+4D)
- Primary outcome: Objective Response Rate (ORR) in the Cohort 4 Non-Hodgkin Lymphoma (NHL) Individual Sub-Cohorts (Cohorts 4A, 4B, 4C, and 4D)
- Primary outcome: Objective Response Rate (ORR) in Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide) Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

## Indexed commentary on KEYNOTE-013 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-013-nct01953692